CG
Price
$38.66
Change
-$0.47 (-1.20%)
Updated
Apr 30, 04:59 PM (EDT)
Capitalization
16.93B
One day until earnings call
DAWN
Price
$7.77
Change
+$0.09 (+1.17%)
Updated
Apr 30, 04:59 PM (EDT)
Capitalization
778.4M
6 days until earnings call
Ad is loading...

CG vs DAWN

Header iconCG vs DAWN Comparison
Open Charts CG vs DAWNBanner chart's image
Carlyle Group (The)
Price$38.66
Change-$0.47 (-1.20%)
Volume$66.53K
Capitalization16.93B
Day One Biopharmaceuticals
Price$7.77
Change+$0.09 (+1.17%)
Volume$33.97K
Capitalization778.4M
CG vs DAWN Comparison Chart
Loading...
CG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DAWN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CG vs. DAWN commentary
May 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CG is a Hold and DAWN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 01, 2025
Stock price -- (CG: $39.13 vs. DAWN: $7.68)
Brand notoriety: CG and DAWN are both not notable
CG represents the Investment Managers, while DAWN is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: CG: 62% vs. DAWN: 78%
Market capitalization -- CG: $16.93B vs. DAWN: $778.4M
CG [@Investment Managers] is valued at $16.93B. DAWN’s [@Biotechnology] market capitalization is $778.4M. The market cap for tickers in the [@Investment Managers] industry ranges from $124.17B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Investment Managers] industry is $5.99B. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CG’s FA Score shows that 1 FA rating(s) are green whileDAWN’s FA Score has 0 green FA rating(s).

  • CG’s FA Score: 1 green, 4 red.
  • DAWN’s FA Score: 0 green, 5 red.
According to our system of comparison, CG is a better buy in the long-term than DAWN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CG’s TA Score shows that 5 TA indicator(s) are bullish while DAWN’s TA Score has 4 bullish TA indicator(s).

  • CG’s TA Score: 5 bullish, 4 bearish.
  • DAWN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CG is a better buy in the short-term than DAWN.

Price Growth

CG (@Investment Managers) experienced а +9.64% price change this week, while DAWN (@Biotechnology) price change was +4.77% for the same time period.

The average weekly price growth across all stocks in the @Investment Managers industry was +2.40%. For the same industry, the average monthly price growth was -0.78%, and the average quarterly price growth was -1.07%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.93%. For the same industry, the average monthly price growth was +3.53%, and the average quarterly price growth was -9.41%.

Reported Earning Dates

CG is expected to report earnings on Jul 24, 2025.

DAWN is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Investment Managers (+2.40% weekly)

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

@Biotechnology (+2.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CG($16.9B) has a higher market cap than DAWN($778M). CG YTD gains are higher at: -21.974 vs. DAWN (-39.384). DAWN has less debt than CG: DAWN (2.6M) vs CG (9.26B). CG has higher revenues than DAWN: CG (1.32B) vs DAWN (131M).
CGDAWNCG / DAWN
Capitalization16.9B778M2,172%
EBITDAN/A-215.24M-
Gain YTD-21.974-39.38456%
P/E Ratio77.57N/A-
Revenue1.32B131M1,011%
Total CashN/A532M-
Total Debt9.26B2.6M355,726%
FUNDAMENTALS RATINGS
CG: Fundamental Ratings
CG
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
49
SMR RATING
1..100
12
PRICE GROWTH RATING
1..100
82
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGDAWN
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 20 days ago
67%
Bearish Trend 15 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
CG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DAWN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STR17.570.04
+0.23%
Sitio Royalties Corp
AGNCP24.65N/A
N/A
AGNC Investment Corp
PEN296.91-0.41
-0.14%
Penumbra
TBPH9.50-0.25
-2.56%
Theravance Biopharma
FEAM4.69-0.51
-9.81%
5E Advanced Materials Inc.